Clinical trial
Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid…
NCT00451035 · Novartis Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT00451035 |
|---|---|
| Title | Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Chronic Phase |
| Official title | A Phase II, Multicentre Study of Oral LBH589 in Patients With Chronic Phase Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two Fusion Gene of the BCR and ABL Genes (BCR-ABL) Tyrosine Kinase Inhibitors |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Myeloid Leukemia in Chronic Phase |
| Intervention type | Drug |
| Interventions | LBH589 |
| Enrollment | 29 |
| Start date | Feb 19, 2007 |
| Primary completion | Apr 13, 2008 |
| Completion | Sep 30, 2008 |
| First posted | Mar 22, 2007 |
| Last update posted | Jul 15, 2021 |
| Countries | Belgium, Germany |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: